Paper
A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib.
Published Mar 8, 2020 · Gege Chen, Ke Hu, Haiguo Sun
Cancer letters
Q1 SJR score
8
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
DCZ0847, alone or in combination with bortezomib, shows potent anti-myeloma activity, inhibiting cell proliferation and promoting apoptosis without harming normal cells.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016
In Latin America, multiple myeloma treatment has shifted towards bortezomib-based therapies, but slower adoption in public clinics and poor progression-free survival in relapsed patients highlight unmet needs.
2019·30citations·Vania Tietsche de Moraes Hungria et al.·British Journal of Haematology
British Journal of Haematology
STAT3: A Promising Therapeutic Target in Multiple Myeloma
STAT3 inhibition shows promise as a promising therapeutic target in multiple myeloma, potentially enhancing existing treatments and promoting cell death in vitro.
2019·65citations·Phyllis S Y Chong et al.·Cancers
Cancers
Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling
Sanguinarine induces mitochondrial and caspase-dependent apoptosis in multiple myeloma cells, generates oxidative stress, and suppresses proliferation, suggesting potential as a therapeutic agent in multiple myeloma.
2019·32citations·Sabah Akhtar et al.·Frontiers in Oncology
Frontiers in Oncology
Cancer statistics, 2019
The overall cancer death rate dropped from 1991 to 2016 by 27%, but socioeconomic inequalities remain, with mortality rates in poor counties being 2x higher for cervical cancer and 40% higher for male lung and liver cancers.
2019·17351citations·R. Siegel et al.·CA: A Cancer Journal for Clinicians
CA: A Cancer Journal for Clinicians
Drug resistance in multiple myeloma.
Understanding molecular mechanisms of drug resistance in multiple myeloma can enhance the use of existing treatments and design more effective therapies.
2018·172citations·P. Robak et al.·Cancer treatment reviews
Cancer treatment reviews
Citations
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
RPS3 is a novel biomarker and therapeutic target in multiple myeloma, mediating drug resistance and shortened survival, with potential therapeutic applications in combination with bortezomib.
2023·5citations·Gege Chen et al.·Haematologica
Haematologica
Targeting transcriptional kinase of CDK7 halts proliferation of multiple myeloma cells by modulating the function of canonical NF-kB pathway and cell cycle regulatory proteins
THZ1 effectively reduces multiple myeloma cell proliferation by targeting CDK7, and when combined with BTZ, shows synergistic reduction in tumor growth in zebrafish embryos.
2023·2citations·Rudra P. Dutta et al.·Translational Oncology
Translational Oncology
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
Ivermectin alone or combined with proteasome inhibitors shows promising anti-multiple myeloma effects, reducing tumor growth and being well-tolerated by experimental animals.
2023·6citations·Hongmei Luo et al.·Cancer letters
Cancer letters
Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis
DARS/GDI2/P4HA2/TRUB1 and P4HA2 are valuable biomarkers for glioblastoma prognosis, with low expression of DARS/GDI2/TRUB1 and high expression of P4HA2 indicating poor prognosis.
2022·5citations·Mengyuan Zhang et al.·PeerJ
PeerJ
Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A
Tubocapsenolide A (TA) shows antitumor activity against osteosarcoma by activating the phosphatase activity of SHP-2, which contributes to its inhibitory effect on the JAK/STAT3 pathway.
2021·14citations·Dongrong Zhu et al.·Journal of Advanced Research
Journal of Advanced Research
Cyy260, a novel small molecule inhibitor, suppresses non-small cell lung cancer cell growth via JAK2/STAT3 pathway.
Cyy260, a novel inhibitor of the JAK2/STAT3 pathway, shows potential in suppressing non-small cell lung cancer cell growth while being less toxic to normal cells.
2021·2citations·Y. Zhuang et al.·American journal of cancer research
American journal of cancer research